The 7th China International Import Expo is coming soon. As a "full-time student" at the CIIE, Johnson&Johnson will focus on the two major business segments of medical technology and innovative pharmaceuticals with the theme of "Innovation in Action, Caring in Heart", showcasing over a hundred innovative products in Hall 7.2 of the medical device and healthcare exhibition area. About a quarter of them will be the first to showcase their products.
At this year's CIIE, Johnson&Johnson's booth has set up a dedicated star product exhibition area, showcasing cutting-edge innovative products including 2 "global debuts" and over 20 "China debuts and debuts". In the field of innovative pharmaceuticals, Rybrevant, a bispecific antibody, is used to treat adult patients with non-small cell lung cancer; reg; Ze Beike, the first and currently the only compound preparation in China for the treatment of BRCA mutant metastatic castration resistant prostate cancer; reg; Waiting for heavyweight exhibits to appear. In the field of medical technology, MONARCH& reg; Impella, a heavyweight innovative product in the field of natural cavity diagnosis and treatment robots and heart failure treatment; reg; CP with SmartAssist interventional left ventricular assist pump, Pronova& for minimally invasive cardiovascular surgery; reg; Suture, innovative paddle design disposable magnetic positioning mapping catheter OPTRELL, MatrixORTHOGNATIC LOCK orthopedic internal fixation system designed specifically for patients with malocclusion in Asia, and TECNISOdyssey innovative intraocular lens designed to provide full range vision; reg; Waiting for cutting-edge medical technology products and solutions from around the world.
At the same time, Johnson&Johnson's medical technology business is innovating in the intersection of biology and technology. Its exhibition area focuses on the fields of surgery, cardiovascular and cerebrovascular diseases, orthopedics, and eye health, bringing a series of more intelligent, minimally invasive, and personalized innovative products and solutions. Through physical exhibitions and multimedia interactive devices, visitors can experience Johnson&Johnson's medical products and technologies firsthand.
The CIIE is an important measure taken by the government to promote high-level opening up to the outside world, support high-quality development, and create a better business environment, "said Zhou Mintao, President of Johnson&Johnson Medical Technology China
Johnson&Johnson's innovative pharmaceutical business is committed to scientifically exploring the future of the pharmaceutical industry. Its exhibition area focuses on heavyweight products in the fields of oncology, immunology, neuroscience, and cardiovascular diseases, fully demonstrating its innovative concept of putting science first, mission first, and patient first, as well as its mission to bring new hope to patients.
Cherry Huang, President of Johnson&Johnson Innovative Pharmaceuticals China, said, "The CIIE is the 'spotlight' for many innovative drugs, the 'catalyst' for promoting cooperation among all parties, and the 'booster' for enterprise development. For Johnson&Johnson Innovative Pharmaceuticals, the CIIE is not only an important opportunity to showcase its numerous innovative drugs and breakthrough therapies, but also an important platform to deepen understanding of the Chinese medical and health market, promote exchanges and cooperation in the medical and health industry. We look forward to using the CIIE platform to accelerate the introduction of more globally leading innovative drugs into China, serve the health needs of more Chinese patients, and promote the continuous development of the medical and health industry
Johnson&Johnson said that in the future, the company will continue to take root in China, give full play to the role of a leader in the medical and health industry, seize the new opportunities brought by market development, while accelerating innovative research and development, actively promote local innovation cooperation, help improve the accessibility and affordability of innovative medical and health products and solutions, and constantly make new positive contributions to the high-quality development of Chinese people's health and medical and health industry.